Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
- Tweets 3,319
- Following 414
- Followers 1,158
- Likes 780
Real-world #DeNi data show #nirogacestat provided durable disease control, tumor responses, and meaningful pain improvement in desmoid tumors. Learn more: hmpgloballearningnetwork.com…
13
Which innovation in pancreatic cancer received a standing ovation at the ASCO 2026 Annual Meeting? Find out in this video featuring Tanios Bekaii-Saab, MD, and Jonathan Catrona, PA-C.
Watch here: hubs.ly/Q04yyS5_0
#ASCO2026 #PancreaticCancer #GICancer
37
Updated phase 3 #COMMANDS results show #luspatercept provided sustained transfusion independence and hemoglobin improvement in ESA-naïve, transfusion-dependent lower-risk #MDS. Learn more: hmpgloballearningnetwork.com…
40
More conversations straight from the debate stage 🎥
We sat down with Efrat Dotan, MD, and Olatunji Alese, MD, prior to today’s debate to take a closer look at their perspectives and what the discussion could mean for clinical practice. Stay tuned!
#OLNGreatDebates
3
82
The debate continues off the stage 🎥
We sat down with Jamie Chaft, MD, FASCO, and Estelamari Rodriguez, MD, MPH, following their debate to dig deeper into their perspectives and the clinical implications of today’s discussion. Stay tuned!
#OLNGreatDebates
1
3
163
Oncology Learning Network retweeted
We're excited! 🎉 Great Debates & Updates in Solid Tumors kicks off tomorrow. Still time to register. Join us for a weekend of expert insights and debate on the latest in oncology care.
#GreatDebatesGU #SolidTumors #OncologyEducation
2
3
308
Results from the phase 3 #EVOKE03 showed that adding sacituzumab govitecan to #pembro failed to improve response in previously untreated patients with PD-L1–high metastatic #NSCLC, despite higher response. Learn more: hmpgloballearningnetwork.com…
1
1
105
AI is one of the hottest topics in oncology. Join Jasmin Hundal, MD, DipABLM, MS, MPH, to learn about the latest updates in AI as presented at the 2026 ASCO annual meeting and how these advances apply to practice for APPs.
🔗 hubs.ly/Q04y9Q920
#OncologyAPP #OncologyAI
45
🚨: The @FDA has approved #belzutifan plus #lenvatinib for patients with advanced clear cell #RCC following PD-1/PD-L1 inhibitor therapy, offering a new combination supported by improved PFS and response compared with #cabozantinib.
Learn more: hmpgloballearningnetwork.com…
72
🚨 @FDA advisors voted in favor of the #Galleri multi-cancer early detection test (@GrailBio) for screening adults over 50, supporting continued review of the first premarket approval application for a multi-cancer early detection test. Learn more: hmpgloballearningnetwork.com…
48
Join Narjust Florez, MD, and Stephanie McDonald, MSN, FNP-BC, AOCNP, as they discuss key lung cancer findings from the 2026 ASCO Annual Meeting and their implications for oncology APPs.
Watch now: hubs.ly/Q04y9PTm0
#lungcancer #ASCO2026annualmeeting
46
🚨 The @FDA has approved #lirafugratinib for previously treated patients with unresectable, locally advanced or metastatic #cholangiocarcinoma harboring an #FGFR2 fusion or rearrangement, expanding biomarker-directed treatment options. Learn more: hmpgloballearningnetwork.com…
49
🚨 The @FDA granted final approval to #Bravnetsa (@LantheusNews), a bioequivalent and therapeutically equivalent lutetium Lu 177 dotatate for adults with SSTR-positive GEP-NETs, expanding radioligand therapy options.
Learn more: hmpgloballearningnetwork.com…
#medtwiter #onctwitter
67
🚨 The @FDA has approved #lanreotide injection (@AmnealPharma) referencing Somatuline Depot (@IpsenUSA), expanding access to long-acting somatostatin analog therapy.
Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
58
Results from the randomized NHS-Galleri trial demonstrated that adding blood-based multicancer early-detection testing to usual care did not significantly reduce late-stage cancer diagnoses, although fewer stage IV cancers were observed. Learn more: hmpgloballearningnetwork.com…
90
In this video interview, Madeline Merrill, AGNP-BC, MSN, discusses care delivery innovations highlighted at the 2026 ASCO Annual Meeting and their implications for oncology APPs.
Learn more: hubs.ly/Q04xYyJZ0
#ASCO2026 #cancercaredelivery
38
Updated #NCCN Guidelines now recommend #rusfertide as a Category 1 option across low- and high-risk polycythemia vera, bringing the first-in-class hepcidin mimetic into clinical management. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
82
🚨 The @FDA granted Fast Track designation to #LYT200 plus a hypomethylating agent for relapsed/refractory high-risk #MDS following early clinical activity, supporting advancement into randomized phase 2 evaluation. Learn more: hmpgloballearningnetwork.com…
60
In this APP Institute case presentation, Mary Steinbach, NP, discusses extramedullary progression after CAR-T therapy in a patient with high-risk multiple myeloma.
Learn more: hubs.ly/Q04y1B_N0
#multiplemyeloma #howitreat
79
Oncology Learning Network retweeted
Two weeks until OLN Great Debates in Solid Tumors arrives in NYC!
Meet some of the local oncology experts joining faculty from across the country to debate the questions shaping solid tumor care.
hmpglobalevents.com/olngreat…
#OLNGreatDebates
4
7
2,827